Integrating cell-signalling pathways with NF-κB and IKK function

Nature Reviews Molecular Cell Biology

Volumn 8, Issue 1, 2007, Pages 49-62

  Perkins, Neil D ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; I KAPPA B; I KAPPA B KINASE BETA; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR;

ADAPTIVE IMMUNITY; CELL ACTIVITY; CELL DEATH; CELL DISRUPTION; CELL FATE; DECISION MAKING; ENZYME ACTIVATION; FEEDBACK SYSTEM; HUMAN; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN MODIFICATION; REGULATORY MECHANISM; REVIEW;

ANIMALS; ENZYME ACTIVATION; HUMANS; I-KAPPA B KINASE; I-KAPPA B PROTEINS; NF-KAPPA B; PROTEIN SUBUNITS; SIGNAL TRANSDUCTION;

EID: 33845768987     PISSN: 14710072     EISSN: 14710080     Source Type: Journal    
DOI: 10.1038/nrm2083     Document Type: Review

References (136)

1. Hayden, M. S. & Ghosh, S. Signaling to NF-κB. Genes Dev. 18, 2195-2224 (2004). This review of the mechanisms of NF-κB activation provides a comprehensive analysis of the NF-κB-signalling pathway.
2. Bonizzi, G. & Karin, M. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 25, 280-288 (2004).
3. Gerondakis, S., Grossmann, M., Nakamura, Y., Pohl, T. & Grumont, R. Genetic approaches in mice to understand Rel/NF-κB and IκB function: transgenics and knockouts. Oncogene 18, 6888-6895 (1999).
4. Pasparakis, M., Luedde, T. & Schmidt-Supprian, M. Dissection of the NF-κB signalling cascade in transgenic and knockout mice. Cell Death Differ. 13, 861-872 (2006). Genetic experiments in mice provide much of the basis for our understanding of the NF-κB and IKK pathway. Reference 3 summarizes fundamental information about different NF-κB-, IκB- and IKK-knockout mouse phenotypes. Reference 4 describes how these mice have been used to study the role of the NF-κB and IKK pathway in physiological processes and human diseases. These reviews are both essential reading.
5. Pahl, H. L. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 18, 6853-6866 (1999).
6. Perkins, N. D. & Gilmore, T. D. Good cop, bad cop: the different faces of NF-κB. Cell Death Differ. 13, 759-772 (2006). Inhibiting NF-κB might not be all good news. This review discusses how NF-κB functions can vary depending on the biological context, and in some cases display apparently contradictory roles.
7. Karin, M., Yamamoto, Y. & Wang, Q. M. The IKK NF-κB system: a treasure trove for drug development. Nature Rev. Drug Discov. 3, 17-26 (2004).
8. Kim, H. J., Hawke, N. & Baldwin, A. S. NF-κB and IKK as therapeutic targets in cancer. Cell Death Differ. 13, 738-747 (2006). Targeting the NF-κB pathway is now recognized as a potential therapy for many inflammatory diseases and cancer. References 7 and 8 provide the rationale for why this is the case and describe the strategies that can be used.
9. Kumar, A., Takada, Y., Boriek, A. M. & Aggarwal, B. B. Nuclear factor-κB: its role in health and disease. J. Mol. Med. 82, 434-448 (2004).
10. Hoffmann, A., Leung, T. H. & Baltimore, D. Genetic analysis of NF-κB/Rel transcription factors defines functional specificities. EMBO J. 22, 5530-5539 (2003).
11. Dobrzanski, P., Ryseck, R. P. & Bravo, R. Differential Interactions of Rel-NF-κB complexes with IκBα determine pools of constitutive and inducible NF-κB activity. EMBO J. 13, 4608-4616 (1994).
12. Perkins, N. D. Post-translational modifications regulating the activity and function of the nuclear factor κB pathway. Oncogene 25, 6717-6730 (2006).
13. Perkins, N. D. Oncogenes, tumor suppressors and p52 NF-κB. Oncogene 22, 7553-7556 (2003).
14. Lin, L., DeMartino, G. N. & Greene, W. C. Cotranslational biogenesis of NF-κB p50 by the 26S proteasome. Cell 92, 819-828 (1998).
15. Cohen, S., Achbert-Weiner, H. & Ciechanover, A. Dual effects of IκB kinase β-mediated phosphorylation on p105 fate: SCF(β-TrCP)-dependent degradation and SCF(β-TrCP)-independent processing. Mol. Cell. Biol. 24, 475-486 (2004).
16. Moorthy, A. K. et al. The 20S proteasome processes NF-κB1 p105 into p50 in a translation-independent manner. EMBO J. 25, 1945-1956 (2006).
17. Kawai, T. & Akira, S. TLR signaling. Cell Death Differ.13, 816-825 (2006).
18. Chen, Z. J. Ubiquitin signalling in the NF-κB pathway. Nature Cell Biol. 7, 758-765 (2005).
19. Krappmann, D. & Scheidereit, C. A pervasive role of ubiquitin conjugation in activation and termination of IκB kinase pathways. EMBO Rep. 6, 321-326 (2005). NEMO-dependent activation of IKKβ involves a complex, ubiquitin-based signalling pathway that is comprehensively described in references 18 and 19.
20. Burns, K. A. & Martinon, F. Inflammatory diseases: is ubiquitinated NEMO at the hub? Curr. Biol. 14, R1040-R1042 (2004).
21. Yamamoto, M. et al. Key function for the Ubc13 E2 ubiquitin-conjugating enzyme in immune receptor signaling. Nature Immunol. 7, 962-970 (2006).
22. Janssens, S. & Tschopp, J. Signals from within: the DNA-damage-induced NF-κB response. Cell Death Differ. 13, 773-784 (2006).
23. Wu, Z. H., Shi, Y., Tibbetts, R. S. & Miyamoto, S. Molecular linkage between the kinase ATM and NF-κB signaling in response to genotoxic stimuli. Science 311, 1141-1146 (2006).
24. Luo, J. L., Kamata, H. & Karin, M. IKK/NF-κB signaling: balancing life and death - a new approach to cancer therapy. J. Clin. Invest. 115, 2625-2632 (2005).
25. Kucharczak, J., Simmons, M. J., Fan, Y. J. & Gelinas, C. To be, or not to be: NF-κB is the answer - role of Rel/NF-κB in the regulation of apoptosis. Oncogene 22, 8961-8982 (2003). Comprehensive review of the complexities surrounding NF-κB-dependent regulation of apoptosis.
26. Herrmann, O. et al. IKK mediates ischemia-induced neuronal death. Nature Med. 11, 1322-1329 (2005).
27. Baxter, F. O. et al. IKKβ/2 induces TWEAK and apoptosis in mammary epithelial cells. Development 133, 3485-3494 (2006).
28. Hu, M. C. et al. IκB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117, 225-237 (2004).
29. Gringhuis, S. I., Garcia-Vallejo, J. J., van Het Hof, B. & van Dijk, W. Convergent actions of IκB kinase β and protein kinase Caδ modulate mRNA stability through phosphorylation of 14-3-3β complexed with tristetraprolin. Mol. Cell. Biol. 25, 6454-6463 (2005).
30. Gao, Z. et al. Serine phosphorylation of insulin receptor substrate 1 by inhibitor κB kinase complex. J. Biol. Chem. 277, 48115-48121 (2002).
31. He, J. et al. Interleukin-1α inhibits insulin signaling with phosphorylating insulin receptor substrate-1 on serine residues in 3T3-L1 adipocytes. Mol. Endocrinol. 20, 114-124 (2006).
32. Nakamori, Y. et al. Myosin motor Myo1c and its receptor NEMO/IKK-γ promote TNF-α-induced serine307 phosphorylation of IRS-1. J. Cell. Biol. 173, 665-671 (2006).
33. Wegener, E. et al. Essential role for IκB kinase β in remodelling Carma1-Bcl10-Malt1 complexes upon T cell activation. Mol. Cell 23, 13-23 (2006).
34. Beinke, S., Robinson, M. J., Hugunin, M. & Ley, S. C. Lipopolysaccharide activation of the TPL-2/MEK/extracellular signal-regulated kinase mitogen-activated protein kinase cascade is regulated by IκB kinase-induced proteolysis of NF-κB1 p105. Mol. Cell. Biol. 24, 9658-9667 (2004).
35. Waterfield, M., Jin, W., Reiley, W., Zhang, M. & Sun, S. C. IκB kinase is an essential component of the Tpl2 signaling pathway. Mol. Cell. Biol. 24, 6040-6048 (2004). References 34 and 35 describe how IKKβ-induced proteolysis of p105 results in TPL2 and MAP kinase-pathway activation.
36. Bouwmeester, T. et al. A physical and functional map of the human TNF-α NF-κB signal transduction pathway. Nature Cell Biol. 6, 97-105 (2004).
37. Zhang, J., Xu, L. G., Han, K. J. & Shu, H. B. Identification of a ZU5 and death domain-containing inhibitor of NF-κB. J. Biol. Chem. 279, 17819-17825 (2004).
38. Li, Z., Zhang, J., Chen, D. & Shu, H. B. Casper/c-FLIP is physically and functionally associated with NF-κB1 p105. Biochem. Biophys. Res. Commun. 309, 980-985 (2003).
39. Ferrier, R. et al. Physical interaction of the bHLH LYL1 protein and NF-κB1 p105. Oncogene 18, 995-1005 (1999).
40. Lee, S. et al. IκB kinase β phosphorylates Dok1 serines in response to TNF, IL-1, or γ radiation. Proc. Natl Acad. Sci. USA 101, 17416-17421 (2004).
41. Westerheide, S. D., Mayo, M. W., Anest, V., Hanson, J. L. & Baldwin, A. S. The putative oncoprotein Bcl-3 induces cyclin D1 to stimulate G1 transition. Mol. Cell. Biol. 21, 8428-8436 (2001).
42. Rocha, S., Martin, A. M., Meek, D. W. & Perkins, N. D. p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-κB subunit with histone deacetylase 1. Mol. Cell. Biol. 23, 4713-4727 (2003).
43. Wu, R. C. et al. Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) coactivator activity by IκB kinase. Mol. Cell. Biol. 22, 3549-3561 (2002).
44. Park, K. J., Krishnan, V., O'Malley, B. W., Yamamoto, Y. & Gaynor, R. B. Formation of an IKKα-dependent transcription complex is required for estrogen receptor-mediated gene activation. Mol. Cell 18, 71-82 (2005). A good example of NF-αB-independent regulation of transcription by IKKα.
45. Albanese, C. et al. IKKα regulates mitogenic signaling through transcriptional induction of cyclin D1 via Tcf. Mol. Biol. Cell 14, 585-599 (2003).
46. Carayol, N. & Wang, C. Y. IKKα stabilizes cytosolic β-catenin by inhibiting both canonical and noncanonical degradation pathways. Cell. Signal. 18, 1941-1946 (2006).
47. Lamberti, C. et al. Regulation of β-catenin function by the IκB kinases. J. Biol. Chem. 276, 42276-42286 (2001).
48. Deng, J. O. et al. β-catenin interacts with and inhibits NF-κB in human colon and breast cancer. Cancer Cell 2, 323-334 (2002).
49. Kim, J. H. et al. Transcriptional regulation of a metastasis suppressor gene by Tip60 and β-catenin complexes. Nature 434, 921-926 (2005).
50. Kwak, Y. T. et al. IκB kinase α regulates subcellular distribution and turnover of cyclin D1 by phosphorylation. J. Biol. Chem. 280, 33945-33952 (2005).
51. Tu, Z. et al. IKK α regulates estrogen-induced cell cycle progression by modulating E2F1 expression. J. Biol. Chem. 281, 6699-6706 (2006).
52. Hoberg, J. E., Yeung, F. & Mayo, M. W. SMRT derepression by the IκB kinase α: a prerequisite to NF-κB transcription and survival. Mol. Cell 16, 245-255 (2004).
53. Hoshino, K. et al. IκB kinase-α is critical for interferon-α production induced by Toll-like receptors 7 and 9. Nature 440, 949-953 (2006).
54. Anest, V. et al. A nucleosomal function for IκB kinase-α in NF-κB-dependent gene expression. Nature 423, 659-663 (2003).
55. Yamamoto, Y., Verma, U. N., Prajapati, S., Kwak, Y. T. & Gaynor, R. B. Histone H3 phosphorylation by IKK-α is critical for cytokine-induced gene expression. Nature 423, 655-659 (2003).
56. Soloaga, A. et al. MSK2 and MSK1 mediate the mitogen- and stress-induced phosphorylation of histone H3 and HMG-14. EMBO J. 22, 2788-2797 (2003).
57. Duncan, E. A., Anest, V., Cogswell, P. & Baldwin, A. S. The kinases MSK1 and MSK2 are required for epidermal growth factor-induced, but not tumor necrosis factor-induced, histone H3 Ser10 phosphorylation. J. Biol. Chem. 281, 12521-12525 (2006).
58. Saccani, S., Pantano, S. & Natoli, G. p38-dependent marking of inflammatory genes for increased NF-κB recruitment. Nature Immunol. 3, 69-75 (2002).
59. Hu, Y. L. et al. IKKα controls formation of the epidermis independently of NF-κB. Nature 410, 710-714 (2001).
60. Ohazama, A. et al. A dual role for IKKα in tooth development. Dev. Cell 6, 219-227 (2004).
61. Verma, U. N., Yamamoto, Y., Prajapati, S. & Gaynor, R. B. Nuclear role of I κB Kinase-γ/NF-κB essential modulator (IKKγ/NEMO) in NF-κB-dependent gene expression. J. Biol. Chem. 279, 3509-3515 (2004).
62. Bracken, C. P., Whitelaw, M. L. & Peet, D. J. Activity of hypoxia-inducible factor 2α is regulated by association with the NF-κB essential modulator. J. Biol. Chem. 280, 14240-14251 (2005).
63. Li, J., Joo, S. H. & Tsai, M. D. An NF-κB-specific inhibitor, IκBα, binds to and inhibits cyclin-dependent kinase 4. Biochemistry 42, 13476-13483 (2003).
64. Chang, N. S. The non-ankyrin C terminus of IκBα physically interacts with p53 in vivo and dissociates in response to apoptotic stress, hypoxia, DNA damage, and transforming growth factor-β1-mediated growth suppression. J. Biol. Chem. 277, 10323-10331 (2002).
65. Zhou, M., Gu, L., Zhu, N., Woods, W. G. & Findley, H. W. Transfection of a dominant-negative mutant NF-κB inhibitor (IκBm) represses p53-dependent apoptosis in acute lymphoblastic leukemia cells: interaction of IkBm and p53. Oncogene 22, 8137-8144 (2003).
66. Dreyfus, D. H., Nagasawa, M., Gelfand, E. W. & Ghoda, L. Y. Modulation of p53 activity by IκBα: evidence suggesting a common phylogeny between NF-κB and p53 transcription factors. BMC Immunol. 6, 12 (2005).
67. Wu, B. Y., Woffendin, C., MacLachlan, I. & Nabel, G. J. Distinct domains of IκB-α inhibit human immunodeficiency virus type 1 replication through NF-κB and Rev. J. Virol. 71, 3161-3167 (1997).
68. Aguilera, C., Hoya-Arias, R., Haegeman, G., Espinosa, L. & Bigas, A. Recruitment of IκBα to the hes1 promoter is associated with transcriptional repression. Proc. Natl Acad. Sci. USA 101, 16537-16542 (2004).
69. Zhong, H. H., Voll, R. E. & Ghosh, S. Phosphorylation of NF-κB p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol. Cell 1, 661-671 (1998).
70. Hoberg, J. E., Popko, A. E., Ramsey, C. S. & Mayo, M. W. IκB kinase α-mediated derepression of SMRT potentiates acetylation of RelA/p65 by p300. Mol. Cell. Biol. 26, 457-471 (2006). Interesting paper describing the complexities of NF-κB-mediated gene regulation, including the role of co-activators, co-repressors and posttranslational modifications.
71. Chen, L. F. & Greene, W. C. Shaping the nuclear action of NF-κB. Nature Rev. Mol. Cell Biol. 5, 392-401 (2004).
72. Rocha, S., Campbell, K. J. & Perkins, N. D. p53- and Mdm2-independent repression of NF-κB transactivation by the ARF tumor suppressor. Mol. Cell 12, 15-25 (2003).
73. Rocha, S., Garrett, M. D., Campbell, K. J., Schumm, K. & Perkins, N. D. Regulation of NF-κB and p53 through activation of ATR and Chk1 by the ARF tumour suppressor. EMBO J. 24, 1157-1169 (2005). Describes how RelA can repress as well as activate transcription and how these contrasting functions can result from subunit phosphorylation and be linked to tumour-suppressor function.
74. Campbell, K. J., Witty, J. M., Rocha, S. & Perkins, N. D. Cisplatin mimics ARF tumor suppressor regulation of RelA (p65) nuclear factor-κB transactivation. Cancer Res. 66, 929-935 (2006).
75. Campbell, K. J., Rocha, S. & Perkins, N. D. Active repression of antiapoptotic gene expression by ReIA(p65) NF-κB. Mol. Cell 13, 853-865 (2004).
76. Strozyk, E., Poppelmann, B., Schwarz, T. & Kulms, D. Differential effects of NF-κB on apoptosis induced by DNA-damaging agents: the type of DNA damage determines the final outcome. Oncogene 25, 6239-6251 (2006).
77. Liu, J. et al. NF-κB is required for UV-induced JNK activation via induction of PKCδ. Mol. Cell 21, 467-480 (2006).
78. Anrather, J., Racchumi, G. & Iadecola, C. cis-acting, element-specific transcriptional activity of differentially phosphorylated nuclear factor-κB. J. Biol. Chem. 280, 244-252 (2005).
79. Thompson, J. E. & Thompson, C. B. Putting the rap on Akt. J. Clin. Oncol. 22, 4217-4226 (2004).
80. Madrid, L. V., Mayo, M. W., Reuther, J. Y. & Baldwin, A. S. Akt stimulates the transactivation potential of the RelA/p65 subunit of NF-κB through utilization of the IκB kinase and activation of the mitogen-activated protein kinase p38. J. Biol. Chem. 276, 18934-18940 (2001).
81. Jeong, S. J., Pise-Masison, C. A., Radonovich, M. F., Park, H. U. & Brady, J. N. Activated AKT regulates NF-κB activation, p53 inhibition and cell survival in HTLV-1-transformed cells. Oncogene 24, 6719-6728 (2005).
82. Haller, D., Russo, M. P., Sartor, R. B. & Jobin, C. IKKβ and phosphatidylinositol 3-kinase/Akt participate in non-pathogenic Gram-negative enteric bacteriainduced RelA phosphorylation and NF-κB activation in both primary and intestinal epithelial cell lines. J. Biol. Chem. 277, 38168-38178 (2002).
83. Mattioli, I. et al. Transient and selective NF-κB p65 serine 536 phosphorylation induced by T cell costimulation is mediated by IκB kinase β and controls the kinetics of p65 nuclear import. J. Immunol. 172, 6336-6344 (2004).
84. Bohuslav, J., Chen, L. F., Kwon, H., Mu, Y. & Greene, W. C. p53 induces NF-κB activation by an IκB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1. J. Biol. Chem. 279, 26115-26125 (2004).
85. Lawrence, T., Bebien, M., Liu, G. Y., Nizet, V. & Karin, M. IKKα limits macrophage NF-κB activation and contributes to the resolution of inflammation. Nature 434, 1138-1143 (2005).
86. Perkins, N. D. Achieving transcriptional specificity with NF-κB. Int. J. Biochem. Cell. Biol. 29, 1433-1448 (1997).
87. Natoli, G., Saccani, S., Bosisio, D. & Marazzi, I. Interactions of NF-κB with chromatin: the art of being at the right place at the right time. Nature Immunol. 6, 439-445 (2005). Interesting review that discusses the importance of chromatin structure, including histone phosphorylation, for the regulation of NF-κB-dependent gene expression.
88. Merika, M. & Thanos, D. Enhanceosomes. Curr. Opin. Genet. Dev. 11, 205-208 (2001).
89. Falvo, J. V., Thanos, D. & Maniatis, T. Reversal of intrinsic DNA bends in the IFN-β gene enhancer by transcription factors and the architectural protein HMG I(Y). Cell 83, 1101-1111 (1995).
90. Thanos, D. & Maniatis, T. Virus induction of human IFNβ gene expression requires the assembly of an enhanceosome. Cell 83, 1091-1100 (1995).
91. Chapman, N. R. & Perkins, N. D. Inhibition of the RelA(p65) NF-κB subunit by Egr-1. J. Biol. Chem. 275, 4719-4725 (2000).
92. Natoli, G. & De Santa, F. Shaping alternative NF-κB-dependent gene expression programs: new clues to specificity. Cell Death Differ. 13, 693-696 (2006).
93. Kumar, A., Lin, Z., SenBanerjee, S. & Jain, M. K. Tumor necrosis factor α-mediated reduction of KLF2 is due to inhibition of MEF2 by NF-κB and histone deacetylases. Mol. Cell. Biol. 25, 5893-5903 (2005).
94. Schumm, K., Rocha, S., Caamano, J. & Perkins, N. D. Regulation of p53 tumour suppressor target gene expression by the p52 NF-κB subunit. EMBO J. 25, 4820-4832 (2006).
95. Nadiminty, N. et al. Stat3 activation of NF-κB p100 processing involves CBP/p300-mediated acetylation. Proc. Natl Acad. Sci. USA 103, 7264-7269 (2006).
96. Kramer, O. H. et al. Acetylation of Stat1 modulates NF-κB activity. Genes Dev. 20, 473-485 (2006).
97. Bosisio, D. et al. A hyper-dynamic equilibrium between promoter-bound and nucleoplasmic dimers controls NF-κB-dependent gene activity. EMBO J. 25, 798-810 (2006).
98. Merika, M., Williams, A. J., Chen, G. Y., Collins, T. & Thanos, D. Recruitment of CBP/p300 by the IFNβ enhanceosome is required for synergistic activation of transcription. Mol. Cell 1, 277-287 (1998).
99. Ainbinder, E. et al. Mechanism of rapid transcriptional induction of tumor necrosis factor α-responsive genes by NF-κB. Mol. Cell. Biol. 22, 6354-6362 (2002).
100. Stathopoulos, A. & Levine, M. Dorsal gradient networks in the Drosophila embryo. Dev. Biol. 246, 57-67 (2002).
101. Jono, H. et al. NF-κB is essential for induction of CYLD, the negative regulator of NF-κB: evidence for a novel inducible autoregulatory feedback pathway. J. Biol. Chem. 279, 36171-36174 (2004).
102. Wertz, I. E. et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling. Nature 430, 694-699 (2004).
103. Trompouki, E. et al. CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members. Nature 424, 793-796 (2003).
104. Brummelkamp, T. R., Nijman, S. M. B., Dirac, A. M. G. & Bernards, R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB. Nature 424, 797-801 (2003).
105. Kovalenko, A. et al. The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination. Nature 424, 801-805 (2003).
106. Massoumi, R., Chmielarska, K., Hennecke, K., Pfeifer, A. & Fassler, R. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-κB signaling. Cell 125, 665-677 (2006).
107. Krappmann, D. et al. The IκB kinase complex and NF-κB act as master regulators of lipopolysaccharide-induced gene expression and control subordinate activation of AP-1. Mol. Cell. Biol. 24, 6488-6500 (2004). This paper is an excellent example of how NF-κB-induced genes, in this case AP1 family members, influence a second wave of NF-κB-dependent gene expression.
108. Werner, S. L., Barken, D. & Hoffmann, A. Stimulus specificity of gene expression programs determined by temporal control of IKK activity. Science 309, 1857-1861 (2005).
109. Covert, M. W., Leung, T. H., Gaston, J. E. & Baltimore, D. Achieving stability of lipopolysaccharide-induced NF-κB activation. Science 309, 1854-1857 (2005).
110. Wietek, C., Miggin, S. M., Jefferies, C. A. & O'Neill, L. A. Interferon regulatory factor-3-mediated activation of the interferon-sensitive response element by Toll-like receptor (TLR) 4 but not TLR3 requires the p65 subunit of NF-κ. J. Biol. Chem. 278, 50923-50931 (2003).
111. Papa, S. et al. The NF-κB-mediated control of the JNK cascade in the antagonism of programmed cell death in health and disease. Cell Death Differ. 13, 712-729 (2006).
112. Nakano, H. et al. Reactive oxygen species mediate crosstalk between NF-κB and JNK. Cell Death Differ. 13, 730-737 (2006). References 111 nd 112 are comprehensive reviews that discuss the mechanisms linking NF-κB activity to the JNK-signalling pathway.
113. Kamata, H. et al. Reactive oxygen species promote TNFα-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120, 649-661 (2005).
114. Zhang, J. Y., Tao, S., Kimmel, R. & Khavari, P. A. CDK4 regulation by TNFR1 and JNK is required for NF-κB-mediated epidermal growth control. J. Cell Biol. 168, 561-566 (2005).
115. Vousden, K. H. & Lu, X. Live or let die: the cell's response to p53. Nature Rev. Cancer 2, 594-604 (2002).
116. Tergaonkar, V., Pando, M., Vafa, O., Wahl, G. & Verma, I. p53 stabilization is decreased upon NFκB activation: a role for NFκB in acquisition of resistance to chemotherapy. Cancer Cell 1, 493-503 (2002). Shows how, in some circumstances, the NF-κB and IKK pathway can suppress p53 activity through inducing HDM2 (or MDM2) expression.
117. Kashatus, D., Cogswell, P. & Baldwin, A. S. Expression of the Bcl-3 proto-oncogene suppresses p53 activation. Genes Dev. 20, 225-235 (2006).
118. Webster, G. A. & Perkins, N. D. Transcriptional cross talk between NF-κB and p53. Mol. Cell. Biol. 19, 3485-3495 (1999).
119. Ryan, K. M., Ernst, M. K., Rice, N. R. & Vousden, K. H. Role of NF-κB in p53-mediated programmed cell death. Nature 404, 892-897 (2000).
120. Fujioka, S. et al. Stabilization of p53 is a novel mechanism for proapoptotic function of NF-κB. J. Biol. Chem. 279, 27549-27559 (2004).
121. Aleyasin, H. et al. Nuclear factor-κB modulates the p53 response in neurons exposed to DNA damage. J. Neurosci. 24, 2963-2973 (2004).
122. Shetty, S. et al. Transcription factor NF-κB differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol. Cell. Biol. 25, 5404-5416 (2005).
123. Eymin, B. et al. p14ARF activates a Tip60-dependent and p53-independent ATM/ATR/CHK pathway in response to genotoxic stress. Mol. Cell. Biol. 26, 4339-4350 (2006).
124. Pascual, G. & Glass, C. K. Nuclear receptors versus inflammation: mechanisms of transrepression. Trends Endocrinol. Metab. 17, 321-327 (2006). Clear and concise discussion of the complex relationship between nuclear receptors and the NF-κB pathway.
125. De Bosscher, K., Vanden Berghe, W. & Haegeman, G. The interplay between the glucocorticoid receptor and nuclear factor-κB or activator protein-1: molecular mechanisms for gene repression. Endocrine Rev. 24, 488-522 (2003).
126. Ito, K., Chung, K. F. & Adcock, I. M. Update on glucocorticoid action and resistance. J. Allergy Clin. Immunol. 117, 522-543 (2006).
127. Auphan, N., DiDonato, J. A., Rosette, C., Helmberg, A. & Karin, M. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 270, 286-290 (1995).
128. Scheinman, R. I., Cogswell, P. C., Lofquist, A. K. & Baldwin, A. S. Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science 270, 283-286 (1995).
129. Sheppard, K. A. et al. Nuclear integration of glucocorticoid receptor and nuclear factor-κB signaling by CREB-binding protein and steroid receptor coactivator-1. J. Biol. Chem. 273, 29291-29294 (1998).
130. Ogawa, S. et al. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 122, 707-721 (2005).
131. Ito, K., Barnes, P. J. & Adcock, I. M. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1β-induced histone H4 acetylation on lysines 8 and 12. Mol. Cell. Biol. 20, 6891-6903 (2000).
132. Luecke, H. F. & Yamamoto, K. R. The glucocorticoid receptor blocks P-TEFb recruitment by NFκB to effect promoter-specific transcriptional repression. Genes Dev. 19, 1116-1127 (2005).
133. Aggarwal, B. B. & Shishodia, S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol. 71, 1397-1421 (2006).
134. Davis, R. E. & Staudt, L. M. Molecular diagnosis of lymphoid malignancies by gene expression profiling. Curr. Opin. Hematol. 9, 333-338 (2002).
135. Hanson, J. L., Hawke, N. A., Kashatus, D. & Baldwin, A. S. The nuclear factor κB subunits RelA/p65 and c-Rel potentiate but are not required for Ras-induced cellular transformation. Cancer Res. 64, 7248-7255 (2004).
136. Greten, F. R. & Karin, M. The IKK/NF-κB activation pathway - a target for prevention and treatment of cancer. Cancer Lett. 206, 193-199 (2004).